The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 39th year as an NCI designated CCC, having received an ?exceptional? overall merit descriptor following its last review in 2010 and now requesting continued federal support for the next five years. Dr. Caligiuri continues in his twelfth year as the OSUCCC Director and his seventh year as CEO of OSU's freestanding James Cancer Hospital. The OSUCCC mission remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 222 OSUCCC full, associate or introductory members are currently served by 14 shared resources and are distributed among our five Research Programs which are: Cancer Control, Translational Therapeutics (formerly Experimental Therapeutics), Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and a new Leukemia Research Program. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach, from etiology through prevention, treatment and survivorship among the major cancers afflicting its population ? lung, colorectal, breast, and prostate. This is done by addressing risky behaviors (tobacco use, obesity, HPV infection and lack of screening) and the higher incidence of and mortality from cancers among the following groups: the poor; the underserved populations of Ohio Appalachia; and inner city African-Americans. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 145 faculty focused in basic, translational and clinical cancer research and cancer medicine, 58 of whom have become OSUCCC members; 2) the addition of 1,326,300 nsf of new space under the full control of the OSUCCC Director at a cost of $1.2 billion and including a new 1.1 million nsf James Cancer Hospital; 3) obtaining a $100M HRSA grant award to construct a state-of-the-art Radiation Oncology Center in the new James Cancer Hospital; 4) a 51% increase in patient accrual to interventional therapeutic trials reflective of robust growth in solid tumor research; 5) the addition of 2 new shared resources at an institutional investment of over $2 million; 6) strong team science as demonstrated by a 12.5% increase in NCI programmatic grant funding (as a fraction of our nearly $45 million in total direct NCI funding); 7) an increase in the mean percent NCI funding proportion to total CCSG funding for our five research programs from 51% to 61%, reflective of increased cancer focus; 8) enhanced collaborative research as demonstrated by a publication portfolio in which 64% of manuscripts are multi-institutional and 84.4% are collaborative (i.e., inter-, intra-programmatic or multi-institutional); and 9) preclinical and clinical development of two agents, one of which changed the landscape in cancer and both of which were subsequently FDA approved. With new recruits and resources in place and building on the momentum of our research work to date, the OSUCCC is poised in these coming five years to take significant steps toward achieving our mission and ultimately our vision of a cancer-free world.

Public Health Relevance

OVERALL NARRATIVE The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach. Research conducted within the five OSUCCC Programs focuses on ways to reduce the higher rates of lung, breast, CRC and prostate cancer as well as the higher prevalence of risky behaviors such as lack of screening, obesity, high tobacco use, and lack of HPV vaccine. Outreach efforts through the OSUCCC address the needs of underserved populations - lower education; poor; inner city African American; rural and urban Hispanic; Appalachian; rural; Amish; and Somali - by providing targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, community gardening, and addressing policy issues (eg, tobacco-free campus).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-41S1
Application #
9378861
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications